IGC Pharma reports Q2 EPS (2c) vs. (2c) last year

Reports Q2 revenue $191,000 vs. $412,000 last year. “This quarter reflects the disciplined execution of our dual strategy in clinical trials and artificial intelligence, positioning IGC to create meaningful shareholder value,” said Ram Mukunda, CEO of IGC Pharma (IGC). “We’ve accelerated our lead Alzheimer’s program past the 50% enrollment mark, demonstrating our operational focus. Simultaneously, we converted a previously cash-negative manufacturing facility into a favorable contract that strengthens our balance sheet. The NIA award underscores that our unique AI platform is not just a concept, but a recognized tool accelerating Alzheimer’s diagnostics. We are confident this progress sets the stage for rapid advancement in the quarters ahead.”